Human T cell hybridomas producing inflammatory lymphokines

The biochemical characterization and medical application of inflammatory lymphokines has been hampered by their limited availability. T cell hybridomas are expected to be excellent sources for the production of large amounts of inflammatory lymphokines, and this article describes a new method for the construction of human T cell hybridomas: human acute lymphatic leukemia cells, treated with an irreversible protein synthesis inhibitor (emetine) and an irreversible RNA synthesis inhibitor (actinomycin D), are fused with mitogen-activated human peripheral blood lymphocytes. The monoclonal human T cell hybridomas thus established have been used for the identification and differentiation between several inflammatory lymphokines